PT  - JOURNAL ARTICLE
AU  - Hyson, Peter R.
AU  - Kao, David P.
TI  - Biomarkers Correspond with Echocardiographic Phenotypes in Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of the RELAX Trial
AID  - 10.1101/2024.04.30.24306660
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.30.24306660
4099  - http://medrxiv.org/content/early/2024/05/02/2024.04.30.24306660.short
4100  - http://medrxiv.org/content/early/2024/05/02/2024.04.30.24306660.full
AB  - Background Little is known about the relationship between structural phenotypes in in heart failure with preserved ejection fraction (HFpEF) and cardiac biomarkers. We used cluster analysis to identify cardiac structural phenotypes and their relationships to biomarkers in HFpEF.Methods and results Latent class analysis (LCA) was applied to echocardiographic data including left atrial enlargement (LAE), diastolic dysfunction (DD), E/e’, EF≤55%, and right ventricular dysfunction from 216 patients enrolled in the RELAX trial. Three structural phenotypes were identified. Phenotype A had the most grade II DD. Phenotype B had the most grade III DD, worst LAE, elevated E/e’ and right ventricular dysfunction. Phenotype C had the least DD and moderate LAE. Phenotypes B and C had prevalent atrial fibrillation (AF). Phenotype B patients had increased carboxy-terminal telopeptide of collagen type I (CITP), cystatin-c (CYSTC), endothelin-1 (ET1), NT-proBNP, and high-sensitivity troponin I (TNI). Type A had the next highest CITP and CYSTC levels while Type C had next highest NT-proBNP.Conclusions Structural HFpEF phenotypes demonstrated different characteristics including cardiac biomarkers. These findings may help explain phenotype-specific differences in natural history and prognosis, and they may represent phenotype-specific pathophysiology that could be amenable to targeted therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the NHLBI: K08 HL125725 (PI: Kao), L30 HL110124 (PI: Kao); and by the American Heart Association: 171G33660301 (PI: Kao)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Colorado Multi-Institutional Review Board gave ethical proval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll primary data used in the present study are available from the NHLBI BioLINCC resource by application. Harmonized data derived from BioLINCC data are available from the authors on reasonable request. https://biolincc.nhlbi.nih.gov/studies/hfn_relax/